75 related articles for article (PubMed ID: 7713256)
1. Immunisation against HSV-1 keratitis with a synthetic gD peptide.
Heiligenhaus A; Wells PA; Foster CS
Eye (Lond); 1995; 9 ( Pt 1)():89-95. PubMed ID: 7713256
[TBL] [Abstract][Full Text] [Related]
2. Preventive effect of local plasmid DNA vaccine encoding gD or gD-IL-2 on herpetic keratitis.
Inoue T; Inoue Y; Nakamura T; Yoshida A; Takahashi K; Inoue Y; Shimomura Y; Tano Y; Fujisawa Y; Aono A; Hayashi K
Invest Ophthalmol Vis Sci; 2000 Dec; 41(13):4209-15. PubMed ID: 11095617
[TBL] [Abstract][Full Text] [Related]
3. [T-cell-induced prevention of HSV-1 keratitis by immunization with the synthetic peptide of glycoprotein D].
Heiligenhaus A; Berra A; Dutt JE; Zhao TZ; Wells PA; Foster CS
Ophthalmologe; 1994 Oct; 91(5):608-16. PubMed ID: 7812092
[TBL] [Abstract][Full Text] [Related]
4. Protection against herpes simplex virus-induced eye disease after vaccination with seven individually expressed herpes simplex virus 1 glycoproteins.
Ghiasi H; Bahri S; Nesburn AB; Wechsler SL
Invest Ophthalmol Vis Sci; 1995 Jun; 36(7):1352-60. PubMed ID: 7775113
[TBL] [Abstract][Full Text] [Related]
5. Protective immunity against ocular herpes infection and disease induced by highly immunogenic self-adjuvanting glycoprotein D lipopeptide vaccines.
Bettahi I; Nesburn AB; Yoon S; Zhang X; Mohebbi A; Sue V; Vanderberg A; Wechsler SL; BenMohamed L
Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4643-53. PubMed ID: 17898288
[TBL] [Abstract][Full Text] [Related]
6. Exacerbation of murine herpes simplex virus-mediated stromal keratitis by Th2 type T cells.
Jayaraman S; Heiligenhaus A; Rodriguez A; Soukiasian S; Dorf ME; Foster CS
J Immunol; 1993 Nov; 151(10):5777-89. PubMed ID: 8228262
[TBL] [Abstract][Full Text] [Related]
7. Immunization with DNA vaccine expressing herpes simplex virus type 1 gD and IL-21 protects against mouse herpes keratitis.
Hu K; He X; Yu F; Yuan X; Hu W; Liu C; Zhao F; Dou J
Immunol Invest; 2011; 40(3):265-78. PubMed ID: 21204603
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of a DNA vaccine encoding herpes simplex virus type 1 (HSV-1) glycoprotein D in decreasing ocular disease severity following corneal HSV-1 challenge.
Frye TD; Chiou HC; Hull BE; Bigley NJ
Arch Virol; 2002 Sep; 147(9):1747-59. PubMed ID: 12209314
[TBL] [Abstract][Full Text] [Related]
9. [Glycoprotein D (5-23) specific Th2-T-cell line induces HSV-1 keratitis].
Heiligenhaus A; Jayaraman S; Soukiasian S; Dorf M; Foster CS
Ophthalmologe; 1995 Aug; 92(4):484-91. PubMed ID: 7549333
[TBL] [Abstract][Full Text] [Related]
10. Immunisation with phage displaying peptides representing single epitopes of the glycoprotein G can give rise to partial protective immunity to HSV-2.
Grabowska AM; Jennings R; Laing P; Darsley M; Jameson CL; Swift L; Irving WL
Virology; 2000 Mar; 269(1):47-53. PubMed ID: 10725197
[TBL] [Abstract][Full Text] [Related]
11. Passive transfer of anti-herpes simplex virus type 2 monoclonal and polyclonal antibodies protect against herpes simplex virus type 1-induced but not herpes simplex virus type 2-induced stromal keratitis.
Ritchie MH; Oakes JE; Lausch RN
Invest Ophthalmol Vis Sci; 1993 Jul; 34(8):2460-8. PubMed ID: 8392037
[TBL] [Abstract][Full Text] [Related]
12. An ocular mucosal administration of nanoparticles containing DNA vaccine pRSC-gD-IL-21 confers protection against mucosal challenge with herpes simplex virus type 1 in mice.
Hu K; Dou J; Yu F; He X; Yuan X; Wang Y; Liu C; Gu N
Vaccine; 2011 Feb; 29(7):1455-62. PubMed ID: 21185849
[TBL] [Abstract][Full Text] [Related]
13. Cholera toxin conjugates for intragastric vaccination against herpes simplex virus type 2.
Drew MD; Estrada AE; Underdown BJ; McDermott MR
Reg Immunol; 1992; 4(2):79-85. PubMed ID: 1503890
[TBL] [Abstract][Full Text] [Related]
14. Comparison of different forms of herpes simplex replication-defective mutant viruses as vaccines in a mouse model of HSV-2 genital infection.
Da Costa XJ; Morrison LA; Knipe DM
Virology; 2001 Sep; 288(2):256-63. PubMed ID: 11601897
[TBL] [Abstract][Full Text] [Related]
15. Role of anti-glycoproteins D (anti-gD) and K (anti-gK) IgGs in pathology of herpes stromal keratitis in humans.
Mott KR; Osorio Y; Maguen E; Nesburn AB; Wittek AE; Cai S; Chattopadhyay S; Ghiasi H
Invest Ophthalmol Vis Sci; 2007 May; 48(5):2185-93. PubMed ID: 17460278
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of a recombinant glycoprotein D subunit vaccine on the development of primary and recurrent ocular infection with herpes simplex virus type 1 in mice.
Keadle TL; Laycock KA; Miller JK; Hook KK; Fenoglio ED; Francotte M; Slaoui M; Stuart PM; Pepose JS
J Infect Dis; 1997 Aug; 176(2):331-8. PubMed ID: 9237697
[TBL] [Abstract][Full Text] [Related]
17. Coexpression of interleukin-2 enhances the immunization effect of a DNA vaccine expressing herpes simplex 1 glycoprotein D.
Li WR; Niu B; Wang JW; Feng ZJ; Wang DX
Acta Virol; 2006; 50(4):251-6. PubMed ID: 17177610
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic efficacy of DNA encoding IFN-alpha1 against corneal HSV-1 infection.
Noisakran SJ; Carr DJ
Curr Eye Res; 2000 May; 20(5):405-12. PubMed ID: 10855035
[TBL] [Abstract][Full Text] [Related]
19. A novel HLA (HLA-A*0201) transgenic rabbit model for preclinical evaluation of human CD8+ T cell epitope-based vaccines against ocular herpes.
Chentoufi AA; Dasgupta G; Christensen ND; Hu J; Choudhury ZS; Azeem A; Jester JV; Nesburn AB; Wechsler SL; BenMohamed L
J Immunol; 2010 Mar; 184(5):2561-71. PubMed ID: 20124097
[TBL] [Abstract][Full Text] [Related]
20. Ocular safety and efficacy of an HSV-1 gD vaccine during primary and latent infection.
Nesburn AB; Ghiasi H; Wechsler SL
Invest Ophthalmol Vis Sci; 1990 Aug; 31(8):1497-502. PubMed ID: 2167298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
